Eli Lilly Reports Positive Phase 3 BRUIN MCL-321 Results for Jaypirca in Mantle Cell Lymphoma

Eli Lilly today announced positive results from the Phase 3 BRUIN MCL-321 trial evaluating Jaypirca (pirtobrutinib) in patients with relapsed or refractory mantle cell lymphoma who had received at least one prior line of therapy. The trial met its primary endpoint, demonstrating a significant improvement in progression-free survival compared to investigator's choice of therapy.